U.S. Markets close in 4 hrs 6 mins

Free Technical Research on Riot Blockchain and Three More Biotech Equities

Stock Research Monitor: PRTA, PTCT, and PULM

LONDON, UK / ACCESSWIRE / July 20, 2018/ If you want a free Stock Review on RIOT sign up now at www.wallstequities.com/registration. On Thursday, July 19, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. US markets saw five out of nine sectors finishing the day in red and four in green. Taking into consideration yesterday’s market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Prothena Corp. PLC (NASDAQ: PRTA), PTC Therapeutics Inc. (NASDAQ: PTCT), Pulmatrix Inc. (NASDAQ: PULM), and Riot Blockchain Inc. (NASDAQ: RIOT). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Prothena

On Thursday, shares in Dun Laoghaire, Ireland headquartered Prothena Corp. PLC recorded a trading volume of 239,001 shares. The stock ended at $15.05, rising 1.90% from the last trading session. The Company’s shares have gained 0.47% in the last month. The stock is trading above its 50-day moving average by 2.11%. Furthermore, shares of Prothena, which focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories, have a Relative Strength Index (RSI) of 53.21. Get the full research report on PRTA for free by clicking below at:

www.wallstequities.com/registration/?symbol=PRTA

PTC Therapeutics

South Plainfield, New Jersey headquartered PTC Therapeutics Inc.’s stock finished yesterday’s session 4.46% higher at $36.55. A total volume of 1.42 million shares was traded, which was above their three months average volume of 1.27 million shares. The Company’s shares have gained 40.04% over the previous three months and 88.40% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 6.72% and 45.13%, respectively. Furthermore, shares of PTC Therapeutics, which focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders, have an RSI of 55.24.

On July 19th, 2018, research firm Credit Suisse initiated an 'Outperform' rating on the Company's stock, with a target price of $49 per share. Get access to our top-rated research, including the free report on PTCT at:


www.wallstequities.com/registration/?symbol=PTCT


Pulmatrix

At the close of trading on Thursday, shares in Lexington, Massachusetts headquartered Pulmatrix Inc. saw a drop of 1.43%, ending the day at $0.48. The stock recorded a trading volume of 435,194 shares. The Company’s shares have advanced 7.91% in the previous three months. The stock is trading below its 50-day moving average by 2.79%. Moreover, shares of Pulmatrix, which develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology, have an RSI of 45.20. Click here to subscribe for a free membership which welcomes you with our report on PULM at:

www.wallstequities.com/registration/?symbol=PULM


Riot Blockchain

Castle Rock, Colorado-based Riot Blockchain Inc.’s shares ended the day 5.93% higher at $6.07 with a total trading volume of 2.38 million shares, which was above their three months average of 700.26 thousand shares. The stock has gained 69.32% over the last twelve months. The Company’s shares are trading below their 50-day moving average by 12.86%. Additionally, shares of Riot Blockchain, which focuses on building, supporting, and operating blockchain technologies, primarily through its cryptocurrency mining operations and other developed businesses, as well as joint ventures, acquisitions, and targeted investments in the sector, have an RSI of 49.17. To get free access to your research report on RIOT, sign up at:

www.wallstequities.com/registration/?symbol=RIOT

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities